Articles tagged with Clear Cells
A pivotal study supports belzutifan approval for patients with advanced kidney cancer, with belzutifan demonstrating a 25% lower risk of progression compared to everolimus. The HIF-2 inhibitor offers a novel therapeutic mechanism in advanced renal cell carcinoma treatment.
A study of nearly half a million women found that endometriosis was associated with a higher risk of ovarian cancer. The risk was particularly elevated among women with ovarian endometriomas or deep infiltrating endometriosis, with a 19-fold increased risk for certain types of ovarian cancer.
A new biomarker has been discovered that can help predict which patients with clear cell renal cancer are at higher risk of recurrence. The 15-gene signature was found to be independently associated with worse disease-free survival and disease-specific survival in two large validation datasets.
A massive study identifies new biomarkers for renal cell carcinoma subtypes, improving diagnosis and treatment. The researchers' integrative analysis of proteogenomic datasets reveals molecular features shared by clear cell and non-clear cell RCC tumors, as well as unique features to various subtypes.
High levels of copper linked to poorer patient outcomes in clear cell renal cell carcinoma (ccRCC) patients, according to NIH-funded University of Cincinnati Cancer Center research. The study aims to identify copper's mechanisms and test potential new treatments for ccRCC.
Researchers at Moffitt Cancer Center found that tumor-associated macrophage clustering in the stromal compartment is associated with poor outcomes. The study developed a score based on gene expression to predict macrophage clustering, which also predicted disease stage and survival.
Researchers identified genes associated with aggressive clear cell renal carcinoma, a subtype of kidney cancer. Anticoagulant therapies may enhance cancer treatment efficacy. Specific genes involved in blood clotting and insulin transport were found to be linked to disease progression.
A standardized non-invasive clear cell likelihood score derived from MRI correlates with the growth rate of small renal masses. Small renal masses with higher scores are more likely to grow faster and may require earlier intervention.
Researchers discovered a new protein, ZHX2, that over-accumulates in cells lacking VHL gene function, promoting cancerous growth and potentially serving as a novel therapeutic target for clear cell renal cell carcinoma. The study's findings suggest a potential new approach to treating the most common type of kidney cancer.
Scientists have successfully programmed cells to self-organize into multi-layered structures reminiscent of simple organisms or embryonic development. These complex cellular assemblies can repair themselves and form complex tissue-like structures, opening doors for wound repair and organ regeneration.
Researchers have discovered that disruptions in iron-sulfur cluster formation can lead to the buildup of fat droplets in cells, a hallmark of conditions like nonalcoholic fatty liver disease. The study provides clues about the biochemical causes of these diseases and may help researchers find new targets for treatment.
Researchers have identified key molecular events and genomic profiles in clear-cell renal carcinoma, a type of kidney cancer. The study's findings could lead to the prediction of metastasis patterns and potentially inform new treatment strategies.
Researchers at The Wistar Institute have identified a new therapeutic target in ovarian clear cell carcinoma, a difficult-to-treat subtype of ovarian cancer. EZH2 inhibition causes regression of ovarian tumors with ARID1A mutation, providing a much-needed therapeutic strategy for clear cell ovarian cancer.
A new study shows that chemical shift techniques in MRI can accurately differentiate clear cell renal cell carcinoma from other types of kidney cancer, enabling better treatment planning. The technique achieved an 83% accuracy rate in distinguishing between tumor types.
Nir Yakoby, a Rutgers-Camden assistant professor of biology, has received a $686,544 NSF CAREER Award to investigate the dynamics and diversity of bone morphogenetic protein signaling in epithelial cells. He aims to understand how changes in this signal create different morphologies in humans and model organisms like Drosophila.
A new treatment protocol for kidney cancer uses molecular imaging and radioimmunotherapy to target clear cell renal carcinoma. The study found that the effectiveness of this therapy may be diminished when used after another anti-cancer drug, sorafenib.
Researchers have identified two genes, ARID1A and PPP2R1A, whose mutations are linked to ovarian clear cell carcinoma, a highly aggressive form of ovarian cancer. The study found that ARID1A mutations were present in over half of the tumors studied, suggesting a significant role in this type of cancer.
A case report describes a rare instance of intrahepatic clear cell cholangiocarcinoma, highlighting its distinct characteristics and low risk of metastasis. The cancer's unique cell structure and lack of mucin production set it apart from conventional HCCs.
A new diagnostic scan using 124I-girentuximab with PET/CT imaging can distinguish between aggressive and less aggressive kidney masses, helping to avoid unnecessary surgeries. The test has a sensitivity and specificity of 86% and 87%, respectively, making it a promising tool for personalized treatment strategies.
A rare case of intrahepatic clear cell cholangiocarcinoma was reported in a Japanese man with hepatitis B virus (HBV) infection. The cancer cells were larger than usual and lacked mucin, differing from conventional ICC cases.
Researchers have discovered a family of transporters called NIPs that can move arsenite across plant cell membranes, reducing toxic arsenic content. The findings suggest that some NIPs can even clear cells of toxic arsenite, potentially enabling plant detoxification.
Researchers identified kisspeptin and GPR54 as independent prognostic biomarkers specific for ovarian clear cell carcinoma. These molecular markers are associated with a favourable prognosis and could potentially be used to monitor disease activity or as therapeutic agents in women with this subtype of ovarian cancer.
A new study at Memorial Sloan Kettering Cancer Center demonstrates the effectiveness of PET imaging in identifying clear cell renal carcinoma, a highly aggressive type of kidney cancer. The technique has a sensitivity of 94% and specificity of 100%, making it a valuable tool for determining whether surgery is needed.